<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02737852</url>
  </required_header>
  <id_info>
    <org_study_id>ST-7609</org_study_id>
    <nct_id>NCT02737852</nct_id>
  </id_info>
  <brief_title>A Single-Center, Clinical Study to Evaluate the Safety of a New Personal Lubricant in Healthy Female Subjects</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Church &amp; Dwight Company, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Church &amp; Dwight Company, Inc.</source>
  <brief_summary>
    <textblock>
      To evaluate the safety of a new personal lubricant when used at least four times weekly for
      two weeks (including at least twice weekly during sexual intercourse for subjects with
      monogamous male partners), in a population consisting of healthy females.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>The new personal lubricant was used by all participants</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With Observed Local Erythema Based on the 5 Point Scoring Scale</measure>
    <time_frame>2 weeks</time_frame>
    <description>Number of subjects with observed local erythema by obstetrician/gynecologist examination as graded on 5 point clinical scale: 0 = normal appearance no irritation, 0.5 = slight, irregular erythema, 1 = mild erythema, 2 = moderate erythema 3 = severe erythema</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Observed Edema Based on the 5 Point Scoring Scale</measure>
    <time_frame>2 weeks</time_frame>
    <description>Number of subjects with observed local edema by obstetrician/gynecologist examination as graded on 5 point clinical scale: 0 = normal appearance no edema, 0.5 = slight edema, 1 = mild edema, 2 = moderate edema 3 = severe edema</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Erythema</condition>
  <condition>Edema</condition>
  <arm_group>
    <arm_group_label>Healthy subject</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subject exposed to Trojan &quot;Chameleon&quot; Personal Lubricant at least four times weekly for two weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Trojan &quot;Chameleon&quot; Personal Lubricant</intervention_name>
    <description>silicone base with sensate</description>
    <arm_group_label>Healthy subject</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  no participation in a similar study 2-weeks prior

          -  may be post-menopausal or have had a hysterectomy

          -  if sexually active, and of child bearing potential, subjects using adequate
             non-barrier method of birth control

          -  free from any vaginal disorders

          -  sexually active and monogamous, heterosexual relationship, and whose male partner is
             willing and able to give informed consent and agrees to engage in sexual intercourse
             at least twice each week during the two-week study or is not sexually active

          -  personal lubricant user and agrees to replace her usual personal lubricant with the
             investigational product

          -  can start regardless of where they are in their cycles

          -  agrees to use the provided investigational product at least four times weekly over the
             two week study period

          -  exhibits no clinically significant evidence of vulvar or vaginal irritation, as
             determined by a study doctor, and no reports of sensory irritation at the baseline
             exam

          -  willing to refrain from introducing any new vaginal products, or using vaginal
             medications or local contraceptives during study

          -  agrees to refrain from douching or using any medications, powder, lotions or personal
             care products in the vulvar or perianal area

          -  willing to use a urine pregnancy test provided to them at baseline and on third visit

          -  standard medical history form on file

          -  signed informed consent

          -  completed HIPAA

          -  dependable and able to follow directions as outlined

          -  receives a score of 0 or 0.5 for erythema and edema: and 0 for sensorial irritation
             (burning, stinging, itching and dryness) during the first examination.

        Exclusion Criteria:

          -  pregnant, nursing or planning a pregnancy

          -  currently using or has used within two weeks prior to the study initiation, any
             systemic or topical corticosteroids, vasoconstrictors, antibiotics,
             anti-inflammatories or antihistamines

          -  known allergies to vaginal or any cosmetic products

          -  reports history of recurrent bladder, vaginal infections or incontinence

          -  exhibits or reports gynecologic abnormalities or has had vaginitis within 60 days
             prior to study initiation

          -  uses a vaginal ring, diaphram or cervical/vault caps, condoms, or condoms with
             spermicide as a means of contraception

          -  participated in a study involving the vaginal area or in an investigational systemic
             drug study within two weeks of study initiation

          -  receives a score higher than 0/5 for erythema, edema or &gt;0 for burning, stinging, or
             itching, during first examination or shows any other sign of mucosal irregularities
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Research Laboratories, LLC</name>
      <address>
        <city>Piscataway</city>
        <state>New Jersey</state>
        <zip>08854</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2016</study_first_submitted>
  <study_first_submitted_qc>April 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2016</study_first_posted>
  <results_first_submitted>July 6, 2017</results_first_submitted>
  <results_first_submitted_qc>July 6, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 2, 2017</results_first_posted>
  <last_update_submitted>August 2, 2017</last_update_submitted>
  <last_update_submitted_qc>August 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erythema</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Healthy Subject</title>
          <description>Healthy subject exposed to Trojan &quot;Chameleon&quot; Personal Lubricant at least four times weekly for two weeks
Trojan &quot;Chameleon&quot; Personal Lubricant: silicone base with sensate</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Healthy Subject</title>
          <description>Healthy subject exposed to Trojan &quot;Chameleon&quot; Personal Lubricant at least four times weekly for two weeks
Trojan &quot;Chameleon&quot; Personal Lubricant: silicone base with sensate</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Age 19-59</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Observed Local Erythema Based on the 5 Point Scoring Scale</title>
        <description>Number of subjects with observed local erythema by obstetrician/gynecologist examination as graded on 5 point clinical scale: 0 = normal appearance no irritation, 0.5 = slight, irregular erythema, 1 = mild erythema, 2 = moderate erythema 3 = severe erythema</description>
        <time_frame>2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Healthy Subject</title>
            <description>Healthy subject exposed to Trojan &quot;Chameleon&quot; Personal Lubricant at least four times weekly for two weeks
Trojan &quot;Chameleon&quot; Personal Lubricant: silicone base with sensate</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Observed Local Erythema Based on the 5 Point Scoring Scale</title>
          <description>Number of subjects with observed local erythema by obstetrician/gynecologist examination as graded on 5 point clinical scale: 0 = normal appearance no irritation, 0.5 = slight, irregular erythema, 1 = mild erythema, 2 = moderate erythema 3 = severe erythema</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Observed Edema Based on the 5 Point Scoring Scale</title>
        <description>Number of subjects with observed local edema by obstetrician/gynecologist examination as graded on 5 point clinical scale: 0 = normal appearance no edema, 0.5 = slight edema, 1 = mild edema, 2 = moderate edema 3 = severe edema</description>
        <time_frame>2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Healthy Subject</title>
            <description>Healthy subject exposed to Trojan &quot;Chameleon&quot; Personal Lubricant at least four times weekly for two weeks
Trojan &quot;Chameleon&quot; Personal Lubricant: silicone base with sensate</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Observed Edema Based on the 5 Point Scoring Scale</title>
          <description>Number of subjects with observed local edema by obstetrician/gynecologist examination as graded on 5 point clinical scale: 0 = normal appearance no edema, 0.5 = slight edema, 1 = mild edema, 2 = moderate edema 3 = severe edema</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Healthy Subject</title>
          <description>Healthy subject exposed to Trojan &quot;Chameleon&quot; Personal Lubricant at least four times weekly for two weeks
Trojan &quot;Chameleon&quot; Personal Lubricant: silicone base with sensate</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Master service agreement and confidentiality agreement in place</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Annahita Ghassemi</name_or_title>
      <organization>Church &amp; Dwight Co., Inc</organization>
      <phone>6098061200</phone>
      <email>annhita.ghassemi@churchdwight.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

